Macy’s outperformed our forecast for a 5% same-store sales decline and $0.15 in earnings per share in the quarter. However, ...

Paramount Has Offered $15 Million to Settle CBS Lawsuit. Trump Wants More. The president's team threatened another lawsuit amid settlement talks. The AI chip maker's shares rose more than 5% after ...

Stocks ended lower as investors awaited Nvidia earnings. The Dow lost 0.6% while the S&P 500 and Nasdaq Composite fell around 0.5%. Businesses and states had sued the government, saying the president ...

Asian stock markets rose Thursday morning after a federal trade court struck down President Trump's global tariffs. Japan's Nikkei Stock Average rose 1.2%, South Korea's Kospi added 1.1% and Australia ...

In short, the stock is more reasonably priced. Nvidia is just dwindling down to a normalized growth rate, one that it can sustain, added Martin, even though he's not sure where that growth will settle ...

Deregulation, of course, refers to the reduction or elimination of government rules and guidelines that typically constrain business operations. The energy and financial-services industries are two ...

Your request for a separate check after 25 years of splitting the bill was also a statement about how you felt about your place among this group of people.

Officials at their May 6-7 meeting reaffirmed the need for a "cautious approach" given increased uncertainty over tariff policies. Speaking at a bitcoin conference in Las Vegas, the vice president ...

Historically, Curaleaf has been primarily focused on the medical cannabis market; however, in May 2019, Curaleaf acquired Cura Partners. The acquisition expanded Curaleaf’s stand-alone East ...

With its 3-star Morningstar Rating, we believe Lowe’s stock is fairly valued compared with our long-term fair value estimate ...

Ansys, meanwhile, will sell PowerArtist, an analysis tool that measures and optimizes the power consumption of digital chips, the FTC said. Synopsys agreed to buy Ansys in January 2024 in a bid to ...

Taysha Gene Therapies disclosed details of a planned trial for its treatment for Rett syndrome and filed for a secondary share offering. The biotechnology company said its Part B trial for TSHA-102, ...